These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7734588)
21. Screening for colorectal cancer: what are the costs? Weller D; Moss J; Hiller J; Thomas D; Edwards J Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012 [TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer screening. Ferrante JM Med Clin North Am; 1996 Jan; 80(1):27-43. PubMed ID: 8569299 [TBL] [Abstract][Full Text] [Related]
23. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Lindholm E; Brevinge H; Haglind E Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785 [TBL] [Abstract][Full Text] [Related]
24. Planning for a possible national colorectal cancer screening programme. Garvican L J Med Screen; 1998; 5(4):187-94. PubMed ID: 9934649 [TBL] [Abstract][Full Text] [Related]
25. Colorectal cancer screening in Australia: an economic evaluation of a potential biennial screening program using faecal occult blood tests. Stone CA; Carter RC; Vos T; John JS Aust N Z J Public Health; 2004 Jun; 28(3):273-82. PubMed ID: 15707175 [TBL] [Abstract][Full Text] [Related]
28. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination. Solomon MJ; McLeod RS CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760 [TBL] [Abstract][Full Text] [Related]
29. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Jørgensen OD; Kronborg O; Fenger C Gut; 2002 Jan; 50(1):29-32. PubMed ID: 11772963 [TBL] [Abstract][Full Text] [Related]
30. Screening for colorectal cancer. Mandel JS Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350 [TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of screening for colorectal cancer in the general population. Frazier AL; Colditz GA; Fuchs CS; Kuntz KM JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892 [TBL] [Abstract][Full Text] [Related]
33. Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value. Edwards JB Pathology; 2005 Dec; 37(6):565-8. PubMed ID: 16373240 [No Abstract] [Full Text] [Related]
34. Fecal occult blood testing: clinical value and limitations. Simon JB Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Lejeune C; Arveux P; Dancourt V; Béjean S; Bonithon-Kopp C; Faivre J Int J Technol Assess Health Care; 2004; 20(4):434-9. PubMed ID: 15609792 [TBL] [Abstract][Full Text] [Related]
36. Fecal occult blood screening for colorectal cancer. Van Dam J; Bond JH; Sivak MV Arch Intern Med; 1995 Dec 11-25; 155(22):2389-402. PubMed ID: 7503597 [TBL] [Abstract][Full Text] [Related]
37. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Hristova L; Hakama M Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial. Whynes DK; J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108 [TBL] [Abstract][Full Text] [Related]
39. Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area. Sorrentino D; Paduano R; Bernardis V; Piccolo A; Bartoli E Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):655-60. PubMed ID: 10418938 [TBL] [Abstract][Full Text] [Related]